85-6400-73　SENP6 Polyclonal Antibody 50ul　BT-AP08208

特徴

• 背景：Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1; MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA; MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al. 2000 [PubMed 10799485]). SENPs also display isopeptidase activity for deconjugation of SUMO-conjugated substrates (Lima and Reverter, 2008 [PubMed 18799455]).

仕様

• サイズ：50ul
• 抗原：The antiserum was produced against synthesized peptide derived from human SENP6. AA range:1042-1091
• 免疫動物：Rabbit
• 交差性：Human
• 適用：IHC-p, ELISA
• クラス：IgG
• クロナリティ：Polyclonal
• 濃度：1 mg/ml
• 別名：SENP6; KIAA0797; SSP1; SUSP1; FKSG6; Sentrin-specific protease 6; SUMO-1-specific protease 1; Sentrin/SUMO-specific protease SENP6
• この商品は法規制を確認しておりません。（法規制によって販売できない場合もございます）

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]